Cytokines in hematopoietic cell transplantation and related cellular therapies

被引:0
|
作者
Bazarbachi, Abdul-Hamid [1 ]
Mapara, Markus Y. [1 ,2 ]
机构
[1] Columbia Univ, New York Presbyterian Hosp, Irving Med Ctr, Div Hematol Oncol, New York, NY 10032 USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, Columbia Ctr Translat Immunol, New York, NY USA
关键词
Cytokines; Hematopoietic cell transplantation; Immune effector cell therapy; Graft-versus-host disease; Cytokine release syndrome; Immune effector cell-associated neurotoxicity; syndrome; JAK inhibitors; Tocilizumab; Anakinra; Axatilimab; VERSUS-HOST-DISEASE; NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; BONE-MARROW-TRANSPLANTATION; RELEASE SYNDROME; INTERLEUKIN-2; THERAPY; PREDICTIVE BIOMARKERS; INITIAL THERAPY; ACUTE GVHD;
D O I
10.1016/j.beha.2025.101600
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines are pleiotropic molecules involved in hematopoiesis, immune responses, infections, and inflammation. They play critical roles in hematopoietic cell transplantation (HCT) and immune effector cell (IEC) therapies, mediating both therapeutic and adverse effects. Thus, cytokines contribute to the immunopathology of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). This review examines cytokine functions in these contexts, their influence on engraftment and immune recovery post-transplantation, and their role in mediating toxicities. We focus on current and potential uses of cytokines to enhance engraftment and potentiate IEC therapies, as well as strategies to mitigate cytokine-mediated complications using cytokine blockers (e.g., tocilizumab, anakinra) and JAK inhibitors (e.g., ruxolitinib). We discuss new insights into GVHD physiology that have led to novel treatments, such as CSF1R blockade, which is effective in refractory chronic GVHD.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections
    Cuvelier, Geoffrey D. E.
    Paulson, Kristjan
    Bow, Eric J.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25
  • [32] Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy
    Kongtim, Piyanuch
    Lee, Dean A.
    Cooper, Laurence J. N.
    Kebriaei, Partow
    Champlin, Richard E.
    Ciurea, Stefan O.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (10) : 1714 - 1720
  • [33] Prevention and treatment of relapse after stem cell transplantation by cellular therapies
    Falkenburg, Fred
    Ruggiero, Eliana
    Bonini, Chaira
    Porter, David
    Miller, Jeff
    Malard, Floran
    Mohty, Mohamad
    Kroger, Nicolaus
    Kolb, Hans Jochem
    BONE MARROW TRANSPLANTATION, 2019, 54 (01) : 26 - 34
  • [34] Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
    Goyal, Amrita
    Foss, Francine
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (1-2) : 41 - 58
  • [35] Prevention and treatment of relapse after stem cell transplantation by cellular therapies
    Fred Falkenburg
    Eliana Ruggiero
    Chaira Bonini
    David Porter
    Jeff Miller
    Floran Malard
    Mohamad Mohty
    Nicolaus Kröger
    Hans Jochem Kolb
    Bone Marrow Transplantation, 2019, 54 : 26 - 34
  • [36] Exogenous administration of immunomodulatory therapies in hematopoietic cell transplantation: an infectious diseases perspective
    Brown, JMY
    CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (04) : 352 - 358
  • [37] Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation
    DeFilipp, Zachariah
    Chen, Yi-Bin
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (12) : 2134 - 2140
  • [38] Complementary therapies for fatigue after hematopoietic stem cell transplantation: an integrative review
    Baydoun, Mohamad
    Barton, Debra L.
    BONE MARROW TRANSPLANTATION, 2018, 53 (05) : 556 - 564
  • [39] Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?
    England, James
    Gupta, Vikas
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) : 453 - 462
  • [40] Complementary therapies for fatigue after hematopoietic stem cell transplantation: an integrative review
    Mohamad Baydoun
    Debra L. Barton
    Bone Marrow Transplantation, 2018, 53 : 556 - 564